Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Treasury Shares (2020 - 2026)

Vaxcyte (PCVX) has 6 years of Treasury Shares data on record, last reported at $3.3 million in Q1 2026.

  • On a quarterly basis, Treasury Shares changed N/A to $3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.3 million, a N/A change, with the full-year FY2025 number at $175513.0, down 85.86% from a year prior.
  • Treasury Shares reached $3.3 million in Q1 2026 per PCVX's latest filing, up from $175513.0 in the prior quarter.
  • Over the last five years, Treasury Shares for PCVX hit a ceiling of $3.3 million in Q1 2026 and a floor of $175513.0 in Q2 2024.
  • A 5-year average of $1.1 million and a median of $763561.0 in 2023 define the central range for Treasury Shares.
  • On a YoY basis, Treasury Shares climbed as much as 1087.38% in 2025 and fell as far as 85.86% in 2025.
  • Tracing PCVX's Treasury Shares over 5 years: stood at $456766.0 in 2022, then soared by 64.96% to $753462.0 in 2023, then skyrocketed by 64.74% to $1.2 million in 2024, then plummeted by 85.86% to $175513.0 in 2025, then soared by 1797.26% to $3.3 million in 2026.
  • Business Quant data shows Treasury Shares for PCVX at $3.3 million in Q1 2026, $175513.0 in Q4 2025, and $2.4 million in Q3 2025.